Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis

Journal of Surgical Research

Volumn 199, Issue 2, 2015, Pages 441-449

  Bohanon, Fredrick J ^a   Wang, Xiaofu ^a   Graham, Brittany M ^a   Ding, Chunyong ^a   Ding, Ye ^a   Radhakrishnan, Geetha L ^a   Rastellini, Cristiana ^a   Zhou, Jia ^a   Radhakrishnan, Ravi S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Derivatives; Fibrosis; Liver; Oridonin; Stellate cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CASPASE 3; COLLAGEN TYPE 1; CYD0682; FIBRONECTIN; LIVER PROTECTIVE AGENT; ORIDONIN; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; KAURANE DERIVATIVE; SCLEROPROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; FIBROGENESIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIVER CELL; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; S PHASE CELL CYCLE CHECKPOINT; STELLATE CELL; ANIMAL; CELL CYCLE CHECKPOINT; CELL LINE; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; HEPATIC STELLATE CELL; LIVER CIRRHOSIS; METABOLISM; PRECLINICAL STUDY;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE; CELL PROLIFERATION; DITERPENES, KAURANE; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR MATRIX PROTEINS; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; RATS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84976299831     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2015.07.042     Document Type: Article

References (41)

1. [1] Hautekeete, M.L., Geerts, A., The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch, 430, 1997, 195.
2. [2] Lee, U.E., Friedman, S.L., Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol, 25, 2011, 195.
3. [3] Puche, J.E., Saiman, Y., Friedman, S.L., Hepatic stellate cells and liver fibrosis. Compr Physiol, 3, 2013, 1473.
4. [4] Novo, E., Cannito, S., Paternostro, C., Bocca, C., Miglietta, A., Parola, M., Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys, 548, 2014, 20.
5. [5] Duval, F., Moreno-Cuevas, J.E., Gonzalez-Garza, M.T., Rodriguez-Montalvo, C., Cruz-Vega, D.E., Liver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cells. Adv Pharm Sci, 2014, 2014, 373295.
6. [6] Lee, Y.A., Wallace, M.C., Friedman, S.L., Pathobiology of liver fibrosis: a translational success story. Gut, 64, 2015, 830.
7. [7] Asahina, K., Hepatic stellate cell progenitor cells. J Gastroenterol Hepatol, 27(Suppl 2), 2012, 80.
8. [8] Li, J.T., Liao, Z.X., Ping, J., Xu, D., Wang, H., Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol, 43, 2008, 419.
9. [9] Winau, F., Hegasy, G., Weiskirchen, R., et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity, 26, 2007, 117.
10. [10] Lemoinne, S., Cadoret, A., El Mourabit, H., Thabut, D., Housset, C., Origins and functions of liver myofibroblasts. Biochim Biophys Acta, 1832, 2013, 948.
11. [11] Tsukamoto, H., Zhu, N.L., Wang, J., Asahina, K., Machida, K., Morphogens and hepatic stellate cell fate regulation in chronic liver disease. J Gastroenterol Hepatol, 27(Suppl 2), 2012, 94.
12. [12] Schuppan, D., Kim, Y.O., Evolving therapies for liver fibrosis. J Clin Invest, 123, 2013, 1887.
13. [13] Chen, G., Wang, K., Yang, B.Y., Tang, B., Chen, J.X., Hua, Z.C., Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol, 40, 2012, 139.
14. [14] Ding, C., Zhang, Y., Chen, H., et al. Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J Med Chem, 56, 2013, 8814.
15. [15] Liu, Z., Ouyang, L., Peng, H., Zhang, W.Z., Oridonin: targeting programmed cell death pathways as an anti-tumour agent. Cell Prolif, 45, 2012, 499.
16. [16] Xu, W., Sun, J., Zhang, T.T., et al. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol Sin, 27, 2006, 1642.
17. [17] Zhou, G.B., Kang, H., Wang, L., et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood, 109, 2007, 3441.
18. [18] Bohanon, F.J., Wang, X., Ding, C., et al. Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. J Surg Res, 190, 2014, 55.
19. [19] Ding, C., Zhang, Y., Chen, H., et al. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J Med Chem, 56, 2013, 5048.
20. [20] Ding, C., Zhang, Y., Chen, H., et al. Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position. Org Lett, 15, 2013, 3718.
21. [21] Ding, C., Wang, L., Chen, H., et al. ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids. Org Biomol Chem, 12, 2014, 8442.
22. [22] Fielding, A.B., Dobreva, I., McDonald, P.C., Foster, L.J., Dedhar, S., Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization. J Cell Biol, 180, 2008, 681.
23. [23] Fujisawa, S., Romin, Y., Barlas, A., et al. Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases. Cytotechnology, 66, 2014, 259.
24. [24] Telford, W.G., King, L.E., Fraker, P.J., Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry, 13, 1992, 137.
25. [25] Kocabayoglu, P., Friedman, S.L., Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed), 5, 2013, 217.
26. [26] Tahashi, Y., Matsuzaki, K., Date, M., et al. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology, 35, 2002, 49.
27. [27] Yoshida, K., Matsuzaki, K., Differential regulation of TGF-β/Smad signaling in hepatic stellate cells between acute and chronic liver injuries. Front Physiol, 3, 2012, 53.
28. [28] Lee, K.W., Thiyagarajan, V., Sie, H.W., et al. Synergistic effect of natural compounds on the fatty acid-induced autophagy of activated hepatic stellate cells. J Nutr Biochem, 25, 2014, 903.
29. [29] Lam, K.S., New aspects of natural products in drug discovery. Trends Microbiol, 15, 2007, 279.
30. [30] Tian, W., Chen, S.Y., Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin. Chin J Integr Med, 19, 2013, 315.
31. [31] Xu, Y., Xue, Y., Wang, Y., Feng, D., Lin, S., Xu, L., Multiple-modulation effects of oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol, 9, 2009, 360.
32. [32] Li S, Liu Y, Liu T, Zhao L, Zhao J, Feng N, Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int J Pharm. Netherlands: 2011 Elsevier B.V, 2011:172.
33. [33] Kelly, J.H., Darlington, G.J., Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2. In Vitro Cell Dev Biol, 25, 1989, 217.
34. [34] March, S., Graupera, M., Rosa Sarrias, M., et al. Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule. Am J Pathol, 170, 2007, 176.
35. [35] Sancar, A., Lindsey-Boltz, L.A., Ünsal-Kaçmaz, K., Linn, S., Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem, 73, 2004, 39.
36. [36] Cummings, B.S., Schnellmann, R.G., Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther, 302, 2002, 8.
37. [37] Bataller, R., Brenner, D.A., Liver fibrosis. J Clin Invest, 115, 2005, 209.
38. [38] Gressner, A.M., Weiskirchen, R., Breitkopf, K., Dooley, S., Roles of TGF-beta in hepatic fibrosis. Front Biosci, 7, 2002, d793.
39. [39] Derynck, R., Zhang, Y.E., Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 425, 2003, 577.
40. [40] Moustakas, A., Heldin, C.H., Non-Smad TGF-beta signals. J Cell Sci, 118, 2005, 3573.
41. [41] Trautwein, C., Friedman, S.L., Schuppan, D., Pinzani, M., Hepatic fibrosis: concept to treatment. J Hepatol, 62, 2015, S15.